Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Abstract of this article Free
space
 arrow  Full Text of this article Free
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Published comments/rapid response letters
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Haas, J. S.
space
  arrow  Seger, A. C.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

SUMMARIES FOR PATIENTS

Potential Savings with Substitution of Generic Drugs for Brand-Name Drugs

7 June 2005 | Volume 142 Issue 11 | Page I-30

Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.

Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.

The summary below is from the full report titled "Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000." It is in the 7 June 2005 issue of Annals of Internal Medicine (volume 142, pages 891-897). The authors are J.S. Haas, K.A. Phillips, E.P. Gerstenberger, and A.C. Seger.


What is the problem and what is known about it so far?
space

Americans are very concerned about the high cost of prescription drugs. Many drugs are available in both generic and brand-name forms. Generic forms are typically less expensive than brand-name forms. Evidence suggests that generic drugs provide the same treatment effects as their brand-name counterparts. For these reasons, substitution of generic drugs for brand-name drugs might be one way to reduce drug spending. A study of prescription drug spending in Medicaid, the public insurance program for Americans who are poor, suggested that generic substitution would have saved $229 million in 2000. However, no studies to date have estimated the potential financial impact of generic substitution beyond the Medicaid population.


Why did the researchers do this particular study?
space

To estimate the potential savings that could result from the substitution of generic drugs for brand-name drugs in the general U.S. adult population.


Who was studied?
space

The study included adults in households that participated in the Medical Expenditure Panel Survey Household Component, 1997–2000, a government survey of a representative sample of the civilian, noninstitutionalized U.S. population.


How was the study done?
space

The survey collects information on the general and health characteristics, insurance coverage, and health care use of all people in sampled households. The researchers used the survey data to identify adults older than 18 years of age who used at least 1 outpatient drug that was available in both generic and brand-name forms (outpatient drugs are drugs used outside of the hospital). The survey also includes information about the amount spent on each brand-name drug by both individuals and their insurance programs. Next, they calculated the potential savings of replacing brand-name drugs with generic drugs, after calculating the average cost of each generic drug and the corresponding brand-name drug for over 7000 drugs used by adults in this sample. Last, they estimated the potential per-person and total savings of generic substitution.


What did the researchers find?
space

Over half (56%) of all outpatient drugs were available in both generic and brand-name forms. However, patients used the generic form in only 61% of cases where both forms were available. If generics had been used in all cases where both forms were available, savings would have been about $46 per person for those younger than age 65 years and about $78 per person for those age 65 years and older. Although the per-person savings does not seem very high, this translates to a national savings of $5.9 billion in the younger group and $2.9 billion in the older group.


What were the limitations of the study?
space

These figures represent averages. Savings for an individual person or their insurance program might differ. The study does not include the costs of drugs for children or drugs prescribed for patients in hospitals, nursing homes, or other institutions.


What are the implications of the study?
space

Substitution of generic drugs for brand-name drugs when both are available would substantially reduce drug spending in the United States.


Related articles in Annals:

Summaries for Patients
Potential Savings with Substitution of Generic Drugs for Brand-Name Drugs
Annals 2005 142: I-30. [Full Text]  



This article has been cited by other articles:


Home page
Arch Intern MedHome page
M. A. Fischer, C. Vogeli, M. Stedman, T. Ferris, M. A. Brookhart, and J. S. Weissman
Effect of Electronic Prescribing With Formulary Decision Support on Medication Use and Cost
Arch Intern Med, December 8, 2008; 168(22): 2433 - 2439.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. Hochman, S. Hochman, D. Bor, and D. McCormick
News Media Coverage of Medication Research: Reporting Pharmaceutical Company Funding and Use of Generic Medication Names
JAMA, October 1, 2008; 300(13): 1544 - 1550.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Public HealthHome page
W. R. Vincent, A. M. Wiesner, and D. T. Steinke
"FREE" PRESCRIPTION DRUG SAMPLES ARE NOT FREE
Am J Public Health, August 1, 2008; 98(8): 1348 - 1349.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. M. Hoffman, N. D. Shah, L. C. Vermeulen, F. Doloresco, P. Grim, R. J. Hunkler, K. M. Hontz, and G. T. Schumock
Projecting future drug expenditures--2008
Am. J. Health Syst. Pharm., February 1, 2008; 65(3): 234 - 253.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C.-W. Tseng, C. M. Mangione, R. H. Brook, E. Keeler, and R. A. Dudley
Identifying Widely Covered Drugs and Drug Coverage Variation Among Medicare Part D Formularies
JAMA, June 20, 2007; 297(23): 2596 - 2602.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
A. S. Kesselheim, M. A. Fischer, and J. Avorn
Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending
Health Aff., November 1, 2006; 25(6): 1637 - 1647.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. M. Paterson, M. Mamdani, D. N. Juurlink, G. Naglie, A. Laupacis, and T. A. Stukel
Clinical consequences of generic warfarin substitution: an ecological study.
JAMA, October 25, 2006; 296(16): 1969 - 1972.
[Full Text] [PDF]


Home page
PediatricsHome page
G. S. Liptak, L. P. Shone, P. Auinger, A. W. Dick, S. A. Ryan, and P. G. Szilagyi
Short-term Persistence of High Health Care Costs in a Nationally Representative Sample of Children
Pediatrics, October 1, 2006; 118(4): e1001 - e1009.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
U. D. Patel and M. M. Davis
Falling into the Doughnut Hole: Drug Spending among Beneficiaries with End-Stage Renal Disease under Medicare Part D Plans
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2546 - 2553.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz
Projecting future drug expenditures--2006
Am. J. Health Syst. Pharm., January 15, 2006; 63(2): 123 - 138.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M.-L. Laroche and L. Merle
Generic Drug Savings
Ann Intern Med, December 6, 2005; 143(11): 844 - 845.
[Full Text] [PDF]


Home page
BMJHome page
A. Tonks
What's new in the other general journals
BMJ, June 25, 2005; 330(7506): 1469 - 1470.
[Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Are generic-drugs so cost-effective ?
Marie-Laure LAROCHE, et al.
Annals Online, 16 Jun 2005 [Full text]
In response to Dr. Laroche
Jennifer S. Haas, et al.
Annals Online, 19 Jul 2005 [Full text]
Substituting Brand Name Levothyroxine Preparations with Generics Would Increase Treatment Costs
Joshua D. Safer, et al.
Annals Online, 21 Jul 2005 [Full text]
Untitled
MORTON H. FIELD
Annals Online, 25 Jul 2005 [Full text]

box Article
 arrow  Table of Contents                
space
 arrow  Abstract of this article Free
space
 arrow  Full Text of this article Free
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Published comments/rapid response letters
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Haas, J. S.
space
  arrow  Seger, A. C.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2005 by the American College of Physicians.